

Certification of Facsimile Transmission	
I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents in the US Patent and Trademark Office on <u>March 25, 2004</u>	
Kathy Mueller	Name of Person Filing Document
<i>Kathy Mueller</i>	Signature of Person Filing Document

RECEIVED
CENTRAL FAX CENTER

MAR 30 2004

P&G Case 9160Q

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :

Ekaterina A. Ponomarenko et al. :

Serial No. 10/758,066 :

Filed January 15, 2004 :

Confirmation No.

Group Art Unit

Examiner

OFFICIAL

For **DISPOSABLE ABSORBENT ARTICLE COMPRISING A DURABLE HYDROPHILIC CORE WRAP**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☒ 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ **37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. ☐ **37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. ☐ **37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. ☐ **Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case)**. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

☐ (2) (For use with applications filed after June 30, 2003.) In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.

OR

☐ (3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. ____, filed ____. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR


☐ (4) Copies of all said documents, except Cite Numbers ____, were submitted and considered in parent application U.S. Patent Application Serial No. ____, filed ____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☐ (6) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.

☐ Additional information is attached.

Respectfully submitted,

By 
Jay A. Krebs
Attorney for Applicant(s)
Registration No. 41,914
(513) 626-4856

Date: 3/25/04
Customer No. 27752
(IDS.doc) (Last Revised 10/10/03)

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/758,066
Confirmation Number	
Filing Date	January 15, 2004
First Named Inventor	Ekaterina A. Ponomarenko
Group Art Unit	
Examiner Name	
Attorney Docket Number	9160Q

SHEET 1 of 2

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.	DOCUMENT NUMBER Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-3,848,594	11-19-1974	Buell	
		US-3,860,003	01-14-1975	Buell	
		US-3,862,472	01-28-1975	Norton et al.	
		US-3,929,135	12-30-1975	Thompson	
		US-3,929,678	12-30-1975	Laughlin et al.	
		US-3,982,302	09-28-1976	Vaalburg	
		US-4,004,323	01-25-1977	Gotchel et al.	
		US-4,057,689	11-08-1977	McConnell	
		US-4,097,965	07-04-1978	Gotchel et al.	
		US-4,130,915	12-26-1978	Gotchel et al.	
		US-4,135,024	01-16-1979	Callahan et al.	
		US-4,176,427	12-04-1979	Neuenschwander	
		US-4,189,896	02-26-1980	Kolbach et al.	
		US-4,207,367	06-10-1980	Baker, Jr.	
		US-4,296,161	10-20-1981	Kaiser et al.	
		US-4,309,469	01-05-1982	Varona	
		US-4,463,045	07-31-1984	Ahr et al.	
		US-4,573,986	03-04-1986	Minetola et al.	
		US-4,609,518	09-02-1986	Curro et al.	
		US-4,610,678	09-09-1986	Weisman et al.	
		US-4,629,643	12-16-1986	Curro et al.	
		US-4,637,859	01-20-1987	Trokhan	
		US-4,673,402	06-16-1987	Weisman et al.	
		US-4,682,942	07-28-1987	Gotchel et al.	
		US-4,695,278	09-22-1987	Lawson	
		US-4,699,622	10-13-1987	Toussant et al.	
		US-4,795,454	01-03-1987	Dragoo	
		US-4,808,178	02-28-1989	Aziz et al.	
		US-4,834,735	05-30-1989	Alamany et al.	
		US-4,846,815	07-11-1989	Scripps	
		US-4,888,231	12-19-1989	Angstadt	
		US-4,909,803	03-20-1990	Aziz et al.	
		US-4,938,753	07-03-1990	Van Gompel et al.	
		US-4,946,527	08-07-1990	Battrell	
		US-4,963,140	10-16-1990	Robertson et al.	
		US-5,026,364	06-25-1991	Robertson	
		US-5,037,416	08-06-1991	Allen et al.	
		US-5,037,416	08-16-1991	Allen et al.	
		US-5,151,092	09-29-1992	Buell et al.	
		US-5,221,274	06-22-1993	Buell et al.	
		US-5,223,096	06-29-1993	Phan et al.	
		US-5,240,562	08-31-1993	Phan et al.	
		US-5,260,345	11-09-1993	DesMarais et al.	
		US-5,269,775	12-14-1993	Freeland et al.	
		US-5,269,775	12-14-1993	Freeland et al.	
		US-5,342,338	08-30-1994	Roe	

